CG Oncology

Biotech & Life Sciences · Irvine, United States · Founded 2010 · IPO 2024

CG Oncology is a healthcare startup that specializes in oncolytic immunotherapy, a type of treatment that uses the body's immune system to fight cancer. The company's primary focus is on developing treatments that can save the bladder in patients suffering from bladder cancer. Their mission is to improve the quality of life for patients with urologic cancers, allowing them to live and work with dignity. Their leading product, cretostimogene grenadenorepvec, is an innovative immunotherapy treatment that is delivered directly into the bladder. This treatment has shown potential in treating Non-Muscle Invasive Bladder Cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG), a common treatment for bladder cancer. The side effects of this treatment are in line with other similar therapies. CG Oncology operates in the healthcare market, specifically in the field of oncology. Their business model revolves around the research, development, and commercialization of their immunotherapy treatments. They generate revenue through the sales of these treatments to healthcare providers and patients. Recently, the company announced that they will be presenting interim Phase 3 data from their BOND-003 study at the upcoming 24th Annual Meeting of the Society of Urologic Oncology. They have also recently appointed new members to their executive team, including a new President and Chief Operating Officer, Chief Technical Officer, and Chief Medical Officer. Keywords: Oncology, Immunotherapy, Bladder Cancer, Urologic Cancers, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer, Healthcare Market, Research and Development, Commercialization, Executive Team.

Valuation $5.21B

Revenue $12M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

18 investors on CG Oncology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Ally Bridge Group

WI Harper Group

Series B+ 16 investors entered at this stage

Perseverance Capital Management

Asian Healthcare Fund

ORI Capital

Kissei Pharmaceutical

Camford Capital

RA Capital Management

Longitude Capital

Decheng Capital

Sirona Capital

Malin Corporation

Acorn Bioventures

BVF Partners

Foresite Capital

Janus Henderson Investors

TCGX

Avidity Partners

Global footprint

Where CG Oncology has talent and traffic

Workforce by country

🇺🇸 United States · Irvine HQ

Book a demo for the full country breakdown

Web traffic by country

23K monthly visits
across markets

🇺🇸 United States64.3%

🇮🇳 India29.1%

🇯🇵 Japan3.5%

🇨🇦 Canada3%

Top 4 markets shown

Talent graph

The shape of CG Oncology's talent

Dealroom maps CG Oncology's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

11 team members profilednamed & role-tagged by Dealroom

198 employeestotal headcount

8 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock CG Oncology's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$6M patent portfolio · 2 active families

Estimated portfolio value

$6M

0.12% of market cap · 398.5× smaller than top peer Illumina ($2.4B)

2 active patent families

Where CG Oncology innovates Bladder cancerCancer researchCell biologyCell specificImmune checkpoint

Where CG Oncology concentrates vs peers

Each axis is a top-10 topic across CG Oncology and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about CG Oncology

An AI-synthesized read of the highest-engagement posts about CG Oncology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CG Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles